Course of DAS in Responders and Nonresponders to Infliximab Therapy
| Response according to criteria of European League Against Rheumatism* | DAS | ||||
| t = 0 wk | t = 2 wk | t = 6 wk | t = 14 wk | t = 22 wk | |
| Good (n = 5) | 5.0 ± 0.3 | 3.9 ± 0.5 | 3.1 ± 0.7 | 3.2 ± 0.3 | 2.7 ± 0.2 |
| Moderate (n = 8) | 5.6 ± 0.8 | 4.3 ± 0.7 | 4.2 ± 0.8 | 4.2 ± 1.0 | 3.9 ± 0.3 |
| None (n = 3) | 6.7 ± 1.0 | 5.1 ± 0.9 | 4.6 ± 1.4 | 6.6 ± 1.3 | 6.3 ± 0.1 |
↵* Clinical response determined at 22 wk.